1. Search Result
Search Result
Results for "

notch

" in MedChemExpress (MCE) Product Catalog:

149

Inhibitors & Agonists

7

Screening Libraries

2

Fluorescent Dye

4

Biochemical Assay Reagents

7

Peptides

14

Inhibitory Antibodies

22

Natural
Products

24

Recombinant Proteins

7

Isotope-Labeled Compounds

14

Antibodies

14

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13526
    YO-01027
    5+ Cited Publications

    Dibenzazepine; DBZ

    Notch γ-secretase Cancer
    YO-01027 (Dibenzazepine;DBZ) is a potent γ-secretase inhibitor with IC50 values of 2.92 and 2.64 nM for Notch and APPL cleavage, respectively.
    YO-01027
  • HY-50752
    LY-411575
    25+ Cited Publications

    Organoid γ-secretase Notch Apoptosis Neurological Disease
    LY-411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with an IC50 of 0.39 nM.
    LY-411575
  • HY-14176
    Compound E
    15+ Cited Publications

    γ-Secretase-IN-1

    γ-secretase Cancer
    Compound E is a γ-secretase inhibitor. Compound E blocks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC50s of 0.24, 0.37, 0.32 nM, respectively.
    Compound E
  • HY-12323
    ISX-9
    10+ Cited Publications

    Isoxazole 9

    Calcium Channel Neurological Disease
    ISX-9 (Isoxazole 9) is a potent inducer of adult neural stem cell differentiation. ISX-9 activates Ca 2+ influx through both voltage-gated Ca 2+ channels and NMDA receptors and increases neuroD expression. ISX-9 also induces cardiomyogenic differentiation of Notch-activated epicardium-derived cells (NECs) .
    ISX-9
  • HY-15185
    Nirogacestat
    10+ Cited Publications

    PF-3084014

    γ-secretase Apoptosis Cancer
    Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .
    Nirogacestat
  • HY-N0133
    Tangeretin
    10+ Cited Publications

    Tangeritin; NSC53909; NSC618905

    Notch Apoptosis Inflammation/Immunology Cancer
    Tangeretin (Tangeritin), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models, and is a Notch-1 inhibitor.
    Tangeretin
  • HY-11102
    RO4929097
    15+ Cited Publications

    γ-secretase Notch Neurological Disease Cancer
    RO4929097 is an orally active γ secretase inhibitor with an IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively .
    RO4929097
  • HY-135145
    Limantrafin
    5+ Cited Publications

    CB-103

    Notch Cancer
    Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity .
    Limantrafin
  • HY-N0711
    Carvacrol
    5+ Cited Publications

    Cymophenol

    Environmental Pollutants Apoptosis Endogenous Metabolite Notch Fungal Bacterial Infection Neurological Disease Inflammation/Immunology Cancer
    Carvacrol is an orally active and blood-brain barrier-permeable monoterpenic phenol that can be extract from an abundant number of aromatic plants, including thyme and oregano, possessing antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, hepatoprotective, spasmolytic, and vasorelaxant properties. Carvacrol also causes cell cycle arrest in G0/G1, downregulates Notch-1, and Jagged-1, and induces apoptosis. Carvacrol is used in low concentrations as a food flavoring ingredient and preservative, as well as a fragrance ingredient in cosmetic formulations .
    Carvacrol
  • HY-12449
    Crenigacestat
    5+ Cited Publications

    LY3039478

    Notch γ-secretase Cancer
    Crenigacestat (LY3039478) is an orally active Notch and γ-secretase inhibitor, with an IC50 of 1 nM in most of the tumor cell lines tested .
    Crenigacestat
  • HY-N3014
    Bruceine D
    4 Publications Verification

    Notch Apoptosis Parasite Infection Cancer
    Bruceine D is a Notch inhibitor with anti-cancer activity and induces apoptosis in several human cancer cells. Bruceine D is an effective botanical insect antifeedant with outstanding systemic properties, causing potent pest growth inhibitory activity . Bruceine D has strong anthelmintic activity against D. intermedius with an EC50 value of 0.57 mg/L .
    Bruceine D
  • HY-N0232
    Psoralidin
    5 Publications Verification

    COX Lipoxygenase Notch Reactive Oxygen Species (ROS) Bacterial Cancer
    Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties . Psoralidin significantly downregulates NOTCH1 signaling. Psoralidin also greatly induces ROS generation .
    Psoralidin
  • HY-10009
    Semagacestat
    10+ Cited Publications

    LY450139

    γ-secretase Amyloid-β Notch Neurological Disease
    Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease .
    Semagacestat
  • HY-137471
    RBPJ Inhibitor-1
    5+ Cited Publications

    RIN1

    Notch Cancer
    RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation .
    RBPJ Inhibitor-1
  • HY-100431
    IMR-1
    5+ Cited Publications

    Notch Cancer
    IMR-1 is a novel class of Notch inhibitor targeting the transcriptional activation with an IC50 of 26 μM. IMR-1 prevents the recruitment of Mastermind-like 1 (Maml1) to the Notch Ternary Complex (NTC) on chromatin, inhibits Notch target gene transcription and dramatically inhibits tumor growth .
    IMR-1
  • HY-P1846
    Jagged-1 (188-204)
    Maximum Cited Publications
    16 Publications Verification

    Notch Cancer
    Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells .
    Jagged-1 (188-204)
  • HY-19369
    L-685458
    5+ Cited Publications

    L-685,458

    γ-secretase Apoptosis Neurological Disease Cancer
    L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC50 of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC50s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .
    L-685458
  • HY-15827
    NSC 405020
    3 Publications Verification

    MMP Cardiovascular Disease Cancer
    NSC 405020 is a specific MMP14 inhibitor. NSC 405020 can directly interact with the hemopexin domain of MMP14. NSC 405020 reduces the expression of full length and active cleaved Notch3 (NICD3). NSC 405020 can be used to research vestibular schwannoma, hemostasis and thrombosis .
    NSC 405020
  • HY-12860
    BMS-986115
    4 Publications Verification

    notch inhibitor 1

    Notch Cancer
    BMS-986115 (Notch inhibitor 1) is a potent Notch inhibitor, with IC50s of 7.8 and 8.5 nM for Notch 1 and Notch 3, respectively. Used in the research of cancer .
    BMS-986115
  • HY-15860
    FLI-06
    5+ Cited Publications

    Notch Cancer
    FLI-06 is an inhibitor of Notch signaling with an EC50 of 2.3 μM.
    FLI-06
  • HY-P1846A
    Jagged-1 (188-204) TFA
    Maximum Cited Publications
    16 Publications Verification

    Notch Cancer
    Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells .
    Jagged-1 (188-204) TFA
  • HY-14399
    Itanapraced
    1 Publications Verification

    CHF5074; CSP-1103

    γ-secretase Apoptosis Neurological Disease
    Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
    Itanapraced
  • HY-15185B
    Nirogacestat dihydrobromide
    10+ Cited Publications

    PF-3084014 dihydrobromide; PF-03084014 dihydrobromide

    γ-secretase Apoptosis Cancer
    Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .
    Nirogacestat dihydrobromide
  • HY-N10790

    Wnt c-Myc Notch Cancer
    RA-V is a cyclic hexapeptide. RA-V has activity against Wnt, Myc and Notch with IC50 values of 50, 75, and 93 ng/mL, respectively. RA-V can be used for the research of cancer-related signaling pathways .
    RA-V
  • HY-12465
    Z-Ile-Leu-aldehyde
    2 Publications Verification

    Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII

    Notch γ-secretase Apoptosis Cancer
    Z-Ile-Leu-aldehyde (Z-IL-CHO) is a potent and competitive peptide aldehyde inhibitor of γ-secretase and notch .
    Z-Ile-Leu-aldehyde
  • HY-B1832
    Prednisone acetate
    1 Publications Verification

    Prednisone 21-acetate

    Glucocorticoid Receptor Interleukin Related Notch Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Prednisone acetate (Prednisone 21-acetate), a glucocorticoid, is an orally active Notch inhibitor. Prednisone acetate has anti-inflammatory activity and can enhance the immune response .
    Prednisone acetate
  • HY-134978A
    (+)SHIN2
    2 Publications Verification

    SHMT Cancer
    (+)SHIN2 is a serine hydroxymethyltransferase (SHMT) inhibitor, whose target can be traced with 13C-serine. (+)SHIN2 increases survival in NOTCH1-driven mouse primary acute lymphoblastic leukemia (T-ALL) in vivo with a synergistic effect with Methotrexate (HY-14519) . (+)SHIN2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (+)SHIN2
  • HY-10016
    E 2012
    5+ Cited Publications

    γ-secretase Neurological Disease
    E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .
    E 2012
  • HY-P99258

    OMP 52M51; Anti-Human notch1 Recombinant Antibody

    Notch Cancer
    Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
    Brontictuzumab
  • HY-15670
    BMS-906024
    3 Publications Verification

    γ-secretase Notch Cancer
    BMS-906024 is an orally active and selective γ-secretase (gamma secretase) inhibitor. BMS-906024 is a potent pan-Notch receptors inhibitor with IC50s of 1.6 nM, 0.7 nM, 3.4 nM, and 2.9 nM for Notch1, -2, -3, and -4 receptors, respectively. BMS-906024 demonstrates broad-spectrum antineoplastic activity .
    BMS-906024
  • HY-123931
    ZLDI-8
    1 Publications Verification

    Notch Phosphatase Apoptosis Cancer
    ZLDI-8 is a Notch activating/cleaving enzyme ADAM-17 inhibitor and inhibits the cleavage of Notch protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins. ZLDI-8 is also a competitive and irreversible tyrosine phosphatase (Lyp) inhibitor with an IC50 of 31.6 μM and a Ki of 26.22 μM. ZLDI-8 inhibits the growth of MHCC97-H cells with an IC50 of 5.32 μM .
    ZLDI-8
  • HY-N5112B
    β,β-Dimethylacrylshikonin
    1 Publications Verification

    Isoarnebin I

    HIF/HIF Prolyl-Hydroxylase Apoptosis Notch NO Synthase Bcl-2 Family Cancer
    β,β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative that can be isolated from Lithospermum erythrorhizon Sieb. et Zucc. β,β-Dimethylacrylshikonin promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. β,β-Dimethylacrylshikonin inhibits Notch-1 activation. β,β-Dimethylacrylshikonin inhibtis tumor cell proliferation, induces tumor cell apoptosis, and inhibits tumor growth .
    β,β-Dimethylacrylshikonin
  • HY-P99261

    OMP 21M18

    Notch Cancer
    Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .
    Demcizumab
  • HY-117113
    JI051
    1 Publications Verification

    Notch Cancer
    JI051 is a stabilizer for the Hes1-PHB2 interaction. JI051 interacts with a cancer-associated protein chaperone prohibitin 2 (PHB2), induces cell-cycle arrest by inhibiting the Notch downstream effector gene Hes1. Anti-cancer activity .
    JI051
  • HY-18614

    Notch γ-secretase Cancer
    LY900009 is a potent and orally active, First-in-class inhibitor of Notch signaling via selective inhibition of the γ-secretase protein (GSI). LY900009 inhibits Notch signalling in tumor cell lines and endothelial cells (IC50=0.005-20 nM). LY900009 can be used for advanced cancer research .
    LY900009
  • HY-P99320

    OMP 59R5; Anti-Human notch2 Recombinant Antibody

    Notch Cancer
    Tarextumab (OMP-59R5) is a cross-reactive, fully human IgG2 antibody that selectively inhibits Notch2 and Notch3 signaling. Tarextumab demonstrates broad-spectrum antitumor efficacy in xenograft models of epithelial tumors. Tarextumab can be used for the study of pancreatic cancer .
    Tarextumab
  • HY-10585R
    Valproic acid (Standard)
    45+ Cited Publications

    VPA (Standard); 2-Propylpentanoic acid (Standard); Dipropylacetic acid (Standard)

    Reference Standards Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite Infection Neurological Disease Metabolic Disease Cancer
    Valproic acid (Dipropylacetic Acid) (Standard) is an analytical standard for valproic acid. This product is intended for research and analytical applications. Valproic acid is an orally active HDAC inhibitor (IC50=0.5-2 mM), inhibits the activity of HDAC1 (IC50=400 μM), and induces the degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits the proliferation of small cell lung cancer (SCLC) cells. Valproic acid is used in the study of epilepsy, bipolar disorder, metabolic diseases, HIV infection, and migraine .
    Valproic acid (Standard)
  • HY-144899

    Notch Cancer
    ASR-490 reduces the viability of HCT116 and SW620 cells by downregulating Notch1 signaling. ASR-490 overcomes Notch1 overexpression and inhibits the growth of HCT/Notch1 transfectants. ASR-490 inhibits the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice .
    ASR-490
  • HY-164404

    Notch Cancer
    NADI-351 is an orally active and potent Notch1 inhibitor that selectively disrupts Notch1 transcription complexes and reduces Notch1 recruitment to target genes. NADI-351 can be utilized in cancer research .
    NADI-351
  • HY-N1510

    Glycosidase Notch Toll-like Receptor (TLR) NF-κB Mucin Reactive Oxygen Species (ROS) Bacterial TGF-beta/Smad Anaplastic lymphoma kinase (ALK) Infection Inflammation/Immunology Cancer
    Kaempferol 3-O-gentiobioside is an orally active flavonoid, with a Ka value of 57 µM against human NOTCH1 and an IC50 value of 50 μM against α-glucosidase. Kaempferol 3-O-gentiobioside inhibits the NOTCH signaling pathway. It downregulates the expression of TLR4 and NLRP3, and suppresses the activation and nuclear translocation of NF-κB. Kaempferol 3-O-gentiobioside inhibits the expression of MUC5AC, reduces nitrite and ROS levels, and attenuates excessive mucus secretion. It exhibits antibacterial activity, reducing the formation and growth of MRSA biofilms. Kaempferol 3-O-gentiobioside blocks the TGF-β/ALK5/Smad signaling pathway and inhibits epithelial-mesenchymal transition. It suppresses the proliferation, migration, invasion and metastatic growth of tumor cells. Kaempferol 3-O-gentiobioside alleviates airway inflammation and mucus hypersecretion in mice with allergic asthma . It reduces the volume of ovarian cancer xenografts in mice. Kaempferol 3-O-gentiobioside can be used in research related to allergic asthma, diabetes, MRSA infection, breast cancer, gastric cancer and ovarian cancer .
    Kaempferol 3-O-gentiobioside
  • HY-P1985

    Notch Cardiovascular Disease Cancer
    Notch 1 (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .
    Notch 1
  • HY-P2203
    SAHM1
    1 Publications Verification

    Notch Inflammation/Immunology
    SAHM1, a peptide mimetic of a dominant negative form of mastermind-like (MAML), inhibits canonical Notch transcription complex formation. SAHM1 can be used for the research of allergic airway inflammation in mice .
    SAHM1
  • HY-100431A
    IMR-1A
    1 Publications Verification

    Notch Drug Metabolite Cancer
    IMR-1A, a acid metabolite of IMR-1, is a Notch inhibitor with an IC50 of 0.5 μM. IMR-1A has a 50-fold increase in potency with respect to IMR-1. IMR-1 can metabolize in vivo to IMR-1A .
    IMR-1A
  • HY-12419

    Notch Cancer
    BMS-983970 is an oral pan-Notch inhibitor for the treatment of multiplecancers .
    BMS-983970
  • HY-164410

    Notch Cancer
    MO-I-1100 is an inhibitor of ASPH (Aspartyl-(Asparaginyl)-β-hydroxylase) enzymatic activity. MO-I-1100 suppresses HCC cell migration, invasion and anchorage independent growth. MO-I-1100 shows antitumor effects through inhibiting Notch signaling cascade in HCC .
    MO-I-1100
  • HY-124484

    Notch Cancer
    JI130 (JI051 derivative ) is a stabilizer for the Hes1-PHB2 interaction. JI130 inhibits the ability of Hes1 to repress transcription. JI130 significantly reduces the tumor growth in a murine pancreatic tumor model and has the potential for managing pancreatic cancer .
    JI130
  • HY-RS09451

    Small Interfering RNA (siRNA) Others

    NOTCH3 Human Pre-designed siRNA Set A contains three designed siRNAs for NOTCH3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NOTCH3 Human Pre-designed siRNA Set A
    NOTCH3 Human Pre-designed siRNA Set A
  • HY-P991423

    21H3RK

    Notch Cancer
    MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .
    MEDI0639
  • HY-104031

    Notch Neurological Disease
    tCFA15 is a trimethyl cyclohexenonic long chain fatty alcohol containing 15 carbon atoms on the side chain, promotes the differentiation of neurons, and may regulates Notch signaling.
    tCFA15
  • HY-158012

    γ-secretase Others
    LY3056480 is a gamma-secretase inhibitor (GSI) that inhibits Notch signaling. LY3056480 improves mild to moderate sensorineural hearing loss and is safe and tolerable. Intratympanic administration of LY3056480 induces hair cell regeneration and partial hearing recovery in mammals .
    LY3056480

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: